Boston, United States
Dewpoint Therapeutics, founded in 2018, stands at the forefront of innovative biotechnology by pioneering the application of biomolecular condensates in drug discovery, a domain previously untapped. With the compelling slogan, "Translating condensate biology into medicine," the company is focused on developing therapeutics across a diverse range of conditions linked to the function or dysfunction of condensates, including oncology, neurodegeneration, cardiopulmonary, and virology.
Dewpoint's proactive collaboration strategy includes partnerships with leading global entities such as Bayer, Novo Nordisk, Evotec, and Chemify, indicating strong industry credibility and support. Their recent $150.00M Series C funding round, led by prominent investors like Arch Venture Partners and Polaris Partners, underscores solid confidence in Dewpoint’s growth potential.
Headquartered in the United States, Dewpoint is strategically positioned in the biotechnology landscape, promising substantial breakthroughs in disease treatments previously deemed untreatable.
